Anti-HGFR/c-Met Antibody (Telisotuzumab) (CAS No 1781223-80-0) is a monoclonal antibody used in cancer research specifically targeting the hepatocyte growth factor receptor (c-Met) pathway This antibody is designed to inhibit the binding of HGF to c-Met disrupting downstream signaling pathways involved in tumor proliferation survival and metastasis It exhibits strong in vitro activity in the nanomolar to low micromolar range indicating potent inhibition of cancer cell growth Telisotuzumab is commonly utilized in various cell models including cancer cell lines and animal studies to assess its therapeutic potential and efficacy It is also employed in drug screening to identify potential combinations or new therapeutic strategies Experimental concentrations typically depend on the specific research design ensuring tailored applicability to diverse experimental frameworks and objectives